They issued a buy rating and a $43.00 target price on the stock. According to their predictions high & low revenue estimates are 77.7 Million and 73 Million respectively. The biopharmaceutical company reported $0.27 EPS for the quarter, topping analysts' consensus estimates of $0.25 by $0.02. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The business had revenue of $61.27 million for the quarter, compared to analyst estimates of $58.05 million. Raymond James & Associates now owns 16,603 shares of the biopharmaceutical company's stock valued at $182,000 after buying an additional 1,781 shares in the last quarter.
Meanwhile, during the same quarter Sucampo Pharmaceuticals, Inc.
Several other equities research analysts have also recently weighed in on SCMP. The stock appeared $18.75 above its 52-week highs and is up 3.62% for the last five trades. Maxim Group cut Sucampo Pharmaceuticals to a hold rating in a research note on Monday, January 1st. UBS Group dropped their target price on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a "buy" rating for the company in a research report on Thursday, October 12th. They issued a "buy" rating and a $14.00 price objective for the company. Out of 3 Wall Street analysts rating Sucampo Pharma, 2 give it "Buy", 0 "Sell" rating, while 1 recommend "Hold". The stock's average target of $17.50 is -4.89% below today's ($18.4) share price.
The investigation by a law firm concerns whether certain officers and directors of Sucampo Pharmaceuticals, Inc. breached their fiduciary duties owed to NASDAQ:SCMP investors in connection with the proposed acquisition. The stock had a trading volume of 4,350,085 shares, compared to its average volume of 4,584,686. Under the terms of the proposed transaction Sun Acquisition Co., a subsidiary of Mallinckrodt, will commence a cash tender offer to purchase all of the outstanding shares of Sucampo Pharmaceuticals' common stock for $18.00 per share. This public company's current market capitalization stands at $862.96 million. However, the institutional investors are observed to own 98.40% of the total shares. Finally, Royce & Associates LP raised its holdings in shares of Sucampo Pharmaceuticals by 9.7% in the third quarter. To answer this question, we will compare the two companies across various metrics including growth, profitability, risk, return, dividends, and valuation.
More notable recent Sucampo Pharmaceuticals, Inc. Ueno Ryuji sold $12.00 million worth of stock or 1.00 million shares. Systematic Financial Management LP acquired a new position in shares of Sucampo Pharmaceuticals in the second quarter worth $1,648,000. Finally, State Board of Administration of Florida Retirement System raised its position in Sucampo Pharmaceuticals by 33.0% in the 3rd quarter.
Nike (NKE) PT Set at $75.00 by Barclays
Deltec Asset Mngmt Ltd Liability Com reported 0.06% in XPO Logistics, Inc. 5,135 were reported by Johnson Fincl Inc. (NYSE:CAH). Northwestern Mutual Wealth Management Company increased Starbucks Corp (SBUX) stake by 9.5% reported in 2017Q3 SEC filing.
In related news, insider Peter A. Kiener sold 50,000 shares of Sucampo Pharmaceuticals stock in a transaction on Thursday, December 7th. This metric reflects the average amount a stock's price has differed from the mean over a period of time. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
ILLEGAL ACTIVITY WARNING: This article was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and worldwide copyright and trademark legislation.
Ameriprise Financial Inc. lifted its holdings in Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The Company's product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis.